

Current Clinical Algorithms and Recent Therapeutic Advances in the Management of Multiple Myeloma and Related Blood Disorders

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Analysis of the IFM/DFCI 2009 trial evaluating immediate or delayed ASCT after RVd induction therapy indicated both progression-free survival (PFS) and overall response rate benefits for patients who underwent treatment with \_\_\_\_\_.
  - a. RVd
  - b. RVd and ASCT
  - c. Neither a nor b (PFS and response rate were equivalent in the 2 study arms)
2. An analysis of the predictive value of minimal residual disease (MRD) in a subset of patients on the IFM/DFCI 2009 trial demonstrated that MRD negativity was highly predictive of PFS.
  - a. True
  - b. False
3. Results from the QuiRedex study indicated a benefit in PFS in patients with \_\_\_\_\_ who received lenalidomide/dexamethasone versus observation.
  - a. Monoclonal gammopathy of undetermined significance
  - b. Smoldering myeloma
  - c. MM
4. The Phase III SWOG-S0777 trial evaluating RVd versus Rd for patients with previously untreated MM without an intent for immediate ASCT demonstrated \_\_\_\_\_ with RVd.
  - a. A significant improvement in PFS
  - b. No improvement in PFS
5. A study presented by Usmani and colleagues at the 2016 ASH meeting demonstrated that daratumumab \_\_\_\_\_ safely be administered via subcutaneous injection.
  - a. Could
  - b. Could not
6. Infusion reactions associated with administration of daratumumab tend to persist over the course of the patient's treatment.
  - a. True
  - b. False
7. The Phase III randomized CASTOR study evaluating daratumumab/bortezomib/dexamethasone versus bortezomib/dexamethasone \_\_\_\_\_ a significant improvement in PFS with the addition of daratumumab for patients with relapsed or refractory MM.
  - a. Demonstrated
  - b. Did not demonstrate
8. Which of the following is the mechanism of action of isatuximab?
  - a. Anti-CD38 monoclonal antibody
  - b. Anti-PD-1/PD-L1 antibody
  - c. Immunomodulatory drug
  - d. Proteasome inhibitor
9. Sensitivity to venetoclax for MM has primarily been observed in patients with t(11;14) disease.
  - a. True
  - b. False
10. Recent studies have demonstrated that the addition of pembrolizumab \_\_\_\_\_ successfully restore activity to either lenalidomide and/or pomalidomide in patients with IMiD-refractory MM.
  - a. Can
  - b. Cannot